U.S. Senator Josh Hawley has initiated a new investigation into pharmaceutical companies involved in the production and distribution of the abortion drug mifepristone, raising renewed concerns among pro-life advocates about both the safety of women and the protection of unborn children.
According to LifeSiteNews, Hawley announced in a formal letter that his office is examining the practices of Danco Laboratories and GenBioPro, two companies responsible for manufacturing and distributing the drug. The investigation will focus on how these companies have marketed mifepristone and whether they have adequately disclosed potential risks associated with its use.
In his letter, Hawley wrote, “I write to inform you that I am opening an investigation into Danco Laboratories and its manufacture, distribution, and marketing practices relating to mifepristone,” according to LifeSiteNews. He further expressed concern about the drug’s safety, stating, “Mounting evidence suggests that mifepristone poses grave risks to women. Yet your company has continued to profit from the widespread distribution of this drug even as serious questions have emerged about hemorrhage, infection, sepsis, and other dangerous complications associated with its use.”
Our Important Lenten Message – Please Watch
The move comes amid broader efforts by Hawley to challenge the widespread use of chemical abortion. According to LifeSiteNews, the senator has also introduced legislation aimed at revoking the Food and Drug Administration’s approval of mifepristone. The proposed Safeguarding Women from Chemical Abortion Act seeks to address what Hawley describes as “harm to women caused by chemical abortion drugs,” while also creating a pathway for women who have experienced complications to pursue legal action.
The abortion pill now accounts for a significant portion of abortions nationwide. Hawley has argued that its growing use raises serious moral and medical concerns, particularly as it pertains to the dignity of human life and the well-being of mothers.
In his letter, Hawley emphasized the need for transparency and accountability, writing, “Congress must determine what your company knew about the harms associated with mifepristone, when it knew it, what it told regulators, and what it may have failed to disclose to women and the public,” according to LifeSiteNews. He added, “The women exposed to the risks of this drug deserve a full accounting.”
As part of the investigation, Hawley has also opened a confidential hotline for women who say they have suffered adverse effects from chemical abortion drugs. According to LifeSiteNews, the hotline is intended to allow women to share their experiences directly with his office.
For Catholics and pro-life advocates, the development underscores ongoing concerns about the moral implications of abortion and the need to uphold both the dignity of human life from conception and the health and safety of mothers. The Church continues to call for compassion, truth, and a deeper commitment to protecting life at every stage.
Your support brings the truth to the world.
Catholic Online News exists because of donors like you. We are 100% funded by people who believe the world deserves real, uncensored news rooted in faith and truth — not corporate agendas. Your gift ensures millions can continue to access the news they can trust — stories that defend life, faith, family, and freedom.
When truth is silenced, your support speaks louder.
